Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Abstract CT209: Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine

(2015) Julia M. Greene et al.   CANCER RESEARCH

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

(2014) E. A. Mittendorf et al.   ANNALS OF ONCOLOGY

AE37: a novel T-cell-eliciting vaccine for breast cancer

(2011) Alan K Sears et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

(2010) S. A. Perez et al.   CLINICAL CANCER RESEARCH

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

(2010) Kevin S Clive et al.   Expert Review of Vaccines

The E75 HER2/neu peptide vaccine

(2008) Elizabeth A. Mittendorf et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) G. E. Peoples et al.   CLINICAL CANCER RESEARCH

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine

(2008) Jarrod P. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY